|
|
|
|
|
|
Sponsored by: |
Pfizer |
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00424411 |
To determine, in subjects with Type 2 Diabetes Mellitus:
Condition | Intervention | Phase |
Diabetes Mellitus, Type 2 |
Drug: Inhaled human insulin (EXUBERA™) |
Phase III |
MedlinePlus related topics: | Diabetes |
ChemIDplus related topics: | Insulin |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Efficacy and Safety of Inhaled Compared With Subcutaneous Human Insulin Therapy in Subjects With Type 2 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial |
Estimated Enrollment: | 300 |
Study Start Date: | September 1999 |
Estimated Study Completion Date: | December 2000 |
Ages Eligible for Study: | 35 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Show 59 Study Locations |
Pfizer |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
To obtain contact information for a study center near you, click here. 
  |
Link to ClinicalStudyResults.org Posting 
  |
Study ID Numbers: | 217-108 |
First Received: | January 17, 2007 |
Last Updated: | February 9, 2007 |
ClinicalTrials.gov Identifier: | NCT00424411 |
Health Authority: | United States: Food and Drug Administration |
|
|
|